Quarterly ResultAug 11, 2026, 08:42 AM
Mereo BioPharma Q2 Net Loss $(7.0M); Cash $30.1M
AI Summary
Mereo BioPharma Group plc reported a net loss of $(7.0) million for Q2 2026, an improvement from $(14.6) million in Q2 2025. However, the company generated no revenue in Q2 or H1 2026, compared to $0.5 million in the prior year periods. Cash and cash equivalents decreased to $30.1 million as of June 30, 2026, from $41.0 million at year-end 2025. The company anticipates continued losses and will require additional funding to support operations beyond the next twelve months.
Key Highlights
- Q2 2026 net loss was $(7.0) million, an improvement from $(14.6) million in Q2 2025.
- H1 2026 net loss was $(13.7) million, down from $(27.5) million in H1 2025.
- Revenue was $0 for Q2 and H1 2026, compared to $0.5 million in prior year periods.
- Cash and cash equivalents stood at $30.1 million as of June 30, 2026.
- Net cash used in operating activities for H1 2026 was $(10.4) million.
- Accumulated deficit reached $(514.5) million as of June 30, 2026.
- Company expects to need additional funding beyond the next 12 months.
Price Impact
More from MREO